Cystic Fibrosis: A Review.
Ong T, Ramsey BW.
JAMA. 2023 Jun 6;329(21):1859-1871. doi: 10.1001/jama.2023.8120.
Pulmonary aspergillosis: a clinical review.
Kousha M, Tadi R, Soubani AO.
Eur Respir Rev. 2011 Sep 1;20(121):156-74. doi: 10.1183/09059180.00001011.
The French compassionate programme of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant.
Burgel PR, Sermet-Gaudelus I, Durieu I, Kanaan R, Macey J, Grenet D, Porzio M, Coolen-Allou N, Chiron R, Marguet C, Douvry B, Dufeu N, Danner-Boucher I, Foucaud P, Lemonnier L, Girodon E, Da Silva J, Martin C; French CF Reference Network study group; Andrejak C, Priou P, Richaud-Thiriez B, Macey J, Montcouquiol S, Douvry B, Remus N, Fanton A, Coolen-Allou N, Gachelin E, Vuillard C, Audousset C, Duthoit L, Bellet-Fraysse E, Languepin J, Durieu I, Nove-Josserand R, Ohlmann C, Raynaud Q, Dufeu N, Chiron R, Billon Y, Danner-Boucher I, Tissot A, Leroy S, Aubourg F, Burnet E, Burgel PR, Carlier N, Da Silva J, Fajac I, Girodon E, Kanaan R, Honoré I, Martin C, Le Bourgeois M, Sermet-Gaudelus I, Le Clainche-Viala L, Corvol H, Dehillotte C, Foucaud P, Lemonnier L, Brinchault G, Ravoninjatovo B, Le Bihan J, Ramel S, Marguet C, Porzio M, Weiss L, Grenet D, de Miranda S, Cosson L, Mankikian J, Pouradier D.
Eur Respir J. 2023 May 5;61(5):2202437. doi: 10.1183/13993003.02437-2022. Print 2023 May.
CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine.
Lopes-Pacheco M.
Front Pharmacol. 2020 Feb 21;10:1662. doi: 10.3389/fphar.2019.01662. eCollection 2019.
A new era for people with cystic fibrosis.
Bierlaagh MC, Muilwijk D, Beekman JM, van der Ent CK.
Eur J Pediatr. 2021 Sep;180(9):2731-2739. doi: 10.1007/s00431-021-04168-y. Epub 2021 Jul 2.
Clinical Manifestation and Treatment of Allergic Bronchopulmonary Aspergillosis.
Agarwal R, Muthu V, Sehgal IS.
Semin Respir Crit Care Med. 2024 Feb;45(1):114-127. doi: 10.1055/s-0043-1776912. Epub 2023 Dec 28.
Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis.
Bacalhau M, Camargo M, Magalhães-Ghiotto GAV, Drumond S, Castelletti CHM, Lopes-Pacheco M.
Pharmaceuticals (Basel). 2023 Mar 8;16(3):410. doi: 10.3390/ph16030410.
Hepatic Manifestations of Cystic Fibrosis.
Sakiani S, Kleiner DE, Heller T, Koh C.
Clin Liver Dis. 2019 May;23(2):263-277. doi: 10.1016/j.cld.2018.12.008. Epub 2019 Feb 21.
The use of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis postliver transplant: A case series.
Ragan H, Autry E, Bomersback T, Hewlett J, Kormelink L, Safirstein J, Shanley L, Lubsch L.
Pediatr Pulmonol. 2022 Feb;57(2):411-417. doi: 10.1002/ppul.25779. Epub 2021 Dec 12.
The Effects of Elexacaftor, Tezacaftor, and Ivacaftor (ETI) on Blood Glucose in Patients With Cystic Fibrosis: A Systematic Review.
Salazar-Barragan M, Taub DR.
Cureus. 2023 Jul 11;15(7):e41697. doi: 10.7759/cureus.41697. eCollection 2023 Jul.
